FGF-23 is elevated by chronic hyperphosphatemia.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2004-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1210/JC.2004-0724PMID 15356053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

  2004cited by this paper
• Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

  2004cited by this paper
• FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

  2003cited by this paper
• Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

  2003cited by this paper
• FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

  2003cited by this paper
• Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

  2003cited by this paper
• Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

  2002cited by this paper
• Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

  2002cited by this paper
• Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

  2001cited by this paper
• The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.

  2001cited by this paper
• Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23

  2000cited by this paper
• EFFECTS OF SERUM CALCIUM LEVEL AND PARATHYROID EXTRACTS ON PHOSPHATE AND CALCIUM EXCRETION IN HYPOPARATHYROID PATIENTS.

  1965cited by this paper

• Obesity and blunted FGF23 response associate with kidney impairment in patients with hypoparathyroidism

  2025cites this paper
• Bone metabolism in primary hyperparathyroidism.

  2025cites this paper
• Elevated FGF23 Despite Biochemical Control Reveals Hidden Mineral Dysregulation in Chronic Hypoparathyroidism

  2025cites this paper
• SIRT6-PAI-1 axis is a promising therapeutic target in aging-related bone metabolic disruption

  2023cites this paper
• Hyperphosphatemia is associated with cardiac valve calcification in chronic hypoparathyroidism

  2022cites this paper
• Intact Fibroblast Growth Factor 23 Regulates Chronic Kidney Disease–Induced Myocardial Fibrosis by Activating the Sonic Hedgehog Signaling Pathway

  2022cites this paper
• Phosphate Metabolism and Pathophysiology in Parathyroid Disorders and Endocrine Tumors

  2021cites this paper
• PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence From Patients With Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated With Synthetic Human PTH 1–34

  2021cites this paper
• FGF23 and Vitamin D Metabolism

  2021cites this paper
• Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy

  2021cites this paper
• Alfacalcidol versus calcitriol in the management of patient with hypoparathyroidism: a randomized control trial.

  2021cites this paper
• Methods for determining vitamin D and its metabolites. Threshold value of bone manifestations

  2021cites this paper
• Effects of FGF23 in the distal nephron

  2021cites this paper
• FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease

  2021cites this paper
• Sclerostin Directly Stimulates Osteocyte Synthesis of Fibroblast Growth Factor-23

  2020cites this paper
• Hyperparathyroidism Which Developed after Resection of a Fibroblast Growth Factor 23-producing Tumor

  2020cites this paper
• Tumor-Induced Osteomalacia

  2020cites this paper
• Evaluation of Serum Level of FGF23 and 1,25(OH)2D3 in Primary Hyperparathyroidism Patients Before and After Parathyroidectomy

  2020cites this paper
• Renal Phosphate Handling: Independent Effects of Circulating FGF23, PTH, and Calcium

  2020cites this paper
• PF-06869206 is selective inhibitor of renal Pi transport: Evidence from in vitro and in vivo studies.

  2020cites this paper
• Auditing the Efficacy and Safety of Alfacalcidol and Calcium Therapy in Idiopathic Hypoparathyroidism

  2019cites this paper
• FGF23 and Associated Disorders of Phosphate Wasting.

  2019cites this paper
• Prospective Evaluation of Perioperative Biochemical Tests to Predict Hypocalcemia After Total Thyroidectomy

  2019cites this paper
• Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases

  2019cites this paper
• The Bone in Renal Transplant Recipients-A Nephrological and Orthopedic Review

  2019cites this paper
• Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron.

  2019cites this paper
• Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients

  2019cites this paper
• Regulation and Effects of FGF23 in Chronic Kidney Disease.

  2019cites this paper
• Hypoparathyroidism and the Kidney.

  2018cites this paper
• Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia

  2018cites this paper
• Tumor-induced osteomalacia

  2018cites this paper
• Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial

  2018cites this paper
• Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients

  2018cites this paper
• Physiological Actions of Fibroblast Growth Factor-23

  2018cites this paper
• Long-term outcome of cataract surgery in patients with idiopathic hypoparathyroidism and its relationship with their calcemic status

  2017cites this paper
• FGF23-Klotho signaling axis in the kidney.

  2017cites this paper
• FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls

  2017cites this paper
• Is Controlling Phosphorus by Decreasing Dietary Protein Intake Beneficial or Harmful in Individuals with Chronic Kidney Disease?

  2017cites this paper
• Effects of phospho- and calciotropic hormones on electrolyte transport in the proximal tubule

  2017cites this paper
• Hypoparathyroidism

  2017cites this paper
• Tumor-induced osteomalacia

  2017cites this paper
• Endocrine Regulation of Phosphate Homeostasis

  2017cites this paper
• The relationship between FGF-23 and ghrelin levels in CKD patients: preliminary data.

  2016cites this paper
• 1,25‐Dihydroxyvitamin D as Monotherapy for XLH: Back to the Future?

  2016influential citation
• Update on FGF23 and Klotho signaling.

  2016cites this paper
• Preclinical studies of VS‐505: a non‐absorbable highly effective phosphate binder

  2016cites this paper
• Mechanisms of soft-tissue mineralization induced by the inhibition of the MEK/ERK pathway or the inhibition of fibroblast growth factor receptors

  2016cites this paper
• The Evaluation of Fibroblast Growth Factor 23 Levels in Hypogonadotropic Hypogonadism

  2016cites this paper
• Prognostic value of FGF23 among patients with end-stage renal disease: a systematic review and meta-analysis.

  2016cites this paper
• Fgf23 and parathyroid hormone signaling interact in kidney and bone.

  2016cites this paper
• FGF23, metabolic risk factors, and blood pressure in patients with primary hyperparathyroidism undergoing parathyroid adenomectomy.

  2016cites this paper
• Painful losses.

  2016cites this paper
• Combined sequence and sequence-structure based methods for analyzing FGF23, CYP24A1 and VDR genes

  2016cites this paper
• Development of in-vitro human and rat proximal tubule cell models as a platform for drug transporter and drug-drug interaction studies

  2015cites this paper
• Other Secondary Hyperparathyroid States

  2015cites this paper
• The PTH/Vitamin D/FGF23 Axis

  2015cites this paper
• Fibroblast Growth Factor 23

  2015cites this paper
• Generation of mice encoding a conditional null allele of Gcm2

  2014cites this paper
• Effects of Calcium on Indices of Bone and Cardiovascular Health, and on Cancer

  2014cites this paper
• VS-501: a novel, nonabsorbed, calcium- and aluminum-free, highly effective phosphate binder derived from natural plant polymer

  2014cites this paper
• Longitudinal FGF23 and Klotho axis characterization in children treated with chronic peritoneal dialysis

  2014cites this paper
• Insufficiency fracture associated with oncogenic osteomalacia.

  2013cites this paper
• Plasma Fibroblast Growth Factor 23 Concentration Is Increased and Predicts Mortality in Patients on the Liver-Transplant Waiting List

  2013cites this paper
• Bone turnover in hyperparathyroidism

  2013cites this paper
• The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.

  2013cites this paper
• FGF-23 and secondary hyperparathyroidism in chronic kidney disease

  2013cites this paper
• A physiologic-based approach to the evaluation of a patient with hyperphosphatemia.

  2013cites this paper
• Association of serum phosphorus concentration with mortality in elderly and nonelderly hemodialysis patients.

  2013cites this paper
• Determinants of Fibroblast Growth Factor-23 and Parathyroid Hormone Variability in Dialysis Patients

  2013cites this paper
• Insights from genetic disorders of phosphate homeostasis.

  2013cites this paper
• Fibrous Dysplasia and Fibroblast Growth Factor-23 Regulation

  2013cites this paper
• Fibroblast growth factor 23: state of the field and future directions.

  2012cites this paper
• Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis B

  2012cites this paper
• Fibroblast growth factor 23--structure, function and role in kidney diseases.

  2012cites this paper
• FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy.

  2012cites this paper
• UPDATE ON FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE

  2012cites this paper
• Relationship of Fibroblast Growth Factor 23 with Left Ventricle Mass Index and Coronary Calcificaton in Chronic Renal Disease

  2012cites this paper
• Phosphate Homeostasis Regulatory Mechanisms

  2012cites this paper
• Enfermedad renal crónica en pediatría y nuevos marcadores moleculares

  2012cites this paper
• Regulation and function of the FGF23/klotho endocrine pathways.

  2012cites this paper
• Vitamin D status in children with chronic kidney disease

  2012cites this paper
• Striking Pathology Gold: A Singular Experience with Daily Reverberations: Sinonasal Hemangiopericytoma (Glomangiopericytoma) and Oncogenic Osteomalacia

  2012cites this paper
• FGF23 and PTH--double agents at the heart of CKD.

  2012cites this paper
• FGF23/Klotho New Regulators of Vitamin D Metabolism

  2011cites this paper
• Case records of the Massachusetts General Hospital. Case 33-2011. A 56-year-old man with hypophosphatemia.

  2011cites this paper
• [Phosphocalcic metabolism: regulation and explorations].

  2011cites this paper
• [FGF-23: just a phosphate metabolism regulator or something else?].

  2011cites this paper
• CHAPTER 28 – Hormones and Disorders of Mineral Metabolism

  2011cites this paper
• Tumor-induced osteomalacia.

  2011cites this paper
• Circulating sclerostin in disorders of parathyroid gland function.

  2011cites this paper
• Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.

  2011cites this paper
• Dietary egg whites for phosphorus control in maintenance haemodialysis patients: a pilot study.

  2011cites this paper
• Osteoporosis following organ transplantation: pathogenesis, diagnosis and management

  2011cites this paper
• Case 33-2011

  2011cites this paper
• Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism.

  2011cites this paper
• FGF23 beyond mineral metabolism: a bridge to cardiovascular disease.

  2011cites this paper
• Prescribed dietary phosphate restriction and survival among hemodialysis patients.

  2011cites this paper
• Matrix extracellular phosphoglycoprotein (MEPE): a putative phosphatonin

  2011cites this paper
• Il Fibroblast Growth Factor-23 (FGF-23)

  2011cites this paper
• Genetic disorders of renal phosphate transport.

  2010cites this paper